Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-09-06
DOI
10.3389/fonc.2021.724620
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
- (2021) Andrés Poveda et al. LANCET ONCOLOGY
- NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
- (2021) Claudia Marchetti et al. Scientific Reports
- Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis
- (2020) V. Ghirardi et al. GYNECOLOGIC ONCOLOGY
- Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma
- (2020) XueJiao Yang et al. Cancer Management and Research
- Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach
- (2020) Claudia Marchetti et al. GYNECOLOGIC ONCOLOGY
- 811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1
- (2020) S. Banerjee et al. ANNALS OF ONCOLOGY
- Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with apatinib
- (2019) Shen-Cun Fang et al. OncoTargets and Therapy
- PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
- (2019) Patrick G. Pilié et al. CLINICAL CANCER RESEARCH
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
- (2019) Kathleen N Moore et al. LANCET ONCOLOGY
- Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer
- (2019) Fiamma Berner et al. JAMA Oncology
- Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases
- (2019) Valerio Gallotta et al. EJSO
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China
- (2019) Jing Ni et al. Journal of Ovarian Research
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
- (2019) Isabelle Ray-Coquard et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study
- (2018) Claudia Marchetti et al. ANNALS OF SURGICAL ONCOLOGY
- Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
- (2018) Giorgia Marisi et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study
- (2017) Xinyang Liu et al. Journal of Hematology & Oncology
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- PARP inhibitors: A new era of targeted therapy
- (2015) Shifalika Tangutoori et al. MATURITAS
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- The DNA damage response and cancer therapy
- (2012) Christopher J. Lord et al. NATURE
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
- (2011) P Österlund et al. BRITISH JOURNAL OF CANCER
- PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases
- (2009) Andreína Peralta-Leal et al. FREE RADICAL BIOLOGY AND MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More